AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Medpace Holdings Inc (NASDAQ:MEDP)
319 USD
-2.500 0.778%Sponsored Reports
Loading...
| Previous Close (in USD) | 321.5 |
|---|---|
| Change | -2.500 0.778% |
| 52 W H/L (in USD) | 459.770/286.755 |
| EBITDA (in USD) | 437.529M |
| PE Ratio | 29.49 |
| Volume | 136894 |
| Diluted Eps TTM | 11.44 |
| Total Assets (in USD) | 1656.828M |
|---|---|
| Total Liabilities (in USD) | 1097.878M |
| Revenue TTM (in USD) | 2070.866M |
| Cash (in USD) | 245.449M |
| Market Cap (in USD) | 10,485.378 M |
| Revenue Per Share TTM | 67.019 |
| Gross Profit TTM (in USD) | 1392.002M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Medpace Holdings Inc
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Employees: 5900
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. August James Troendle M.D. | Chairman & CEO | 1956 |
| 2. | Mr. Jesse J. Geiger BBA, CPA | Pres | 1974 |
| 3. | Mr. Kevin M. Brady | CFO & Treasurer | 1974 |
| 4. | Ms. Susan E. Burwig | Exec. VP of Operations | 1963 |
| 5. | Mr. Stephen P. Ewald | Chief Compliance Officer, Gen. Counsel & Corp. Sec. | 1969 |
| 6. | Brandon Ebken | Chief Information Officer | NA |
| 7. | Ms. Lauren Morris | Associate Director of Investors Relations | NA |
| 8. | Mr. Todd Meyers | VP of Bus. Devel. & Marketing | NA |
| 9. | Mr. Weimin Gai MS | Sr. VP of Biometrics | NA |
| 10. | Mr. Daniel O'Leary | Sr. VP of Medical Department | NA |
Peers
Sector: Healthcare
Industry: Diagnostics & Research
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
TMO
Thermo Fisher Scientific Inc |
-10.860 2.530% | 426.56 | 34.710 | 23.866 | 4.622 | 4.428 | 5.293 | 20.886 |
|
DHR
Danaher Corporation |
-3.540 1.742% | 202.05 | 29.090 | 28.011 | 5.669 | 3.198 | 5.999 | 19.094 |
|
A
Agilent Technologies Inc |
-2.240 1.845% | 120.34 | 34.360 | 26.385 | 6.587 | 7.136 | 6.781 | 23.557 |
|
IDXX
IDEXX Laboratories Inc |
-0.990 0.181% | 546.46 | 49.990 | 45.662 | 11.293 | 27.850 | 11.461 | 34.457 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | 282.86M | 201.852M | 168.532M | 124.832M | 93.951M |
| Minority Interest | - | - | - | - | - |
| Net Income | 245.368M | 181.848M | 145.384M | 100.443M | 73.185M |
| Selling General Administrative | 131.4M | 108.421M | 92.156M | 95.245M | 75.681M |
| Gross Profit | 432.438M | 328.155M | 278.726M | 245.697M | 215.53M |
| Reconciled Depreciation | 22.341M | 21.119M | 19.528M | 23.189M | 38.801M |
| Ebit | 278.697M | 198.615M | 167.042M | 127.263M | 102.108M |
| Ebitda | 301.038M | 219.734M | 186.57M | 150.452M | 140.909M |
| Depreciation And Amortization | 22.341M | 21.119M | 19.528M | 23.189M | 38.801M |
| Operating Income | 278.697M | 198.615M | 167.042M | 127.263M | 101.048M |
| Other Operating Expenses | 1181.299M | 943.762M | 758.883M | 733.706M | 603.541M |
| Interest Expense | 2.905M | -0.105M | 0.307M | 1.568M | 8.157M |
| Tax Provision | 37.492M | 20.004M | 23.148M | 24.389M | 20.766M |
| Interest Income | - | - | - | 1.568M | 8.157M |
| Net Interest Income | -2.905M | -0.105M | 0.307M | -1.568M | -8.157M |
| Income Tax Expense | 37.492M | 20.004M | 23.148M | 24.389M | 20.766M |
| Total Revenue | 1459.996M | 1142.377M | 925.925M | 860.969M | 704.589M |
| Total Operating Expenses | 153.741M | 129.54M | 111.684M | 118.434M | 114.482M |
| Cost Of Revenue | 1027.558M | 814.222M | 647.199M | 615.272M | 489.059M |
| Total Other Income Expense Net | 4.163M | 3.237M | 1.49M | -2.431M | 1.06M |
| Net Income From Continuing Ops | 245.368M | 181.848M | 145.384M | 100.443M | 73.185M |
| Net Income Applicable To Common Shares | 245.368M | 181.848M | 145.384M | 100.164M | 72.894M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 1656.828M | 1352.495M | 1659.935M | 1390.677M | 1143.071M |
| Intangible Assets | 35.809M | 38.008M | 41.36M | 46.474M | 54.35M |
| Other Current Assets | 49.979M | 52.293M | 43.176M | 34.923M | 29.446M |
| Total Liab | 1097.878M | 966.108M | 707.007M | 584.898M | 416.788M |
| Total Stockholder Equity | 558.95M | 386.387M | 952.928M | 805.779M | 726.283M |
| Other Current Liab | 40.441M | 257.672M | 27.612M | 23.527M | 18.987M |
| Common Stock | 0.308M | 0.309M | 0.36M | 0.355M | 0.36M |
| Capital Stock | 0.308M | 0.309M | 0.36M | 0.355M | 0.36M |
| Retained Earnings | -221.645M | -359.827M | 234.984M | 115.229M | 68.109M |
| Good Will | 662.396M | 662.396M | 662.396M | 662.396M | 662.396M |
| Other Assets | - | 69.212M | 42.556M | 123.139M | 9.853M |
| Cash | 245.449M | 28.265M | 461.304M | 277.766M | 131.92M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 925.131M | 803.47M | 557.217M | 440.11M | 343.002M |
| Current Deferred Revenue | 559.86M | 462.729M | 344.641M | 255.664M | 192.359M |
| Net Debt | -103.327M | 160.602M | -330.339M | -162.623M | -86.708M |
| Short Term Debt | 292.961M | 50M | 159.286M | 134.367M | 109.252M |
| Short Long Term Debt | - | 50M | - | - | - |
| Short Long Term Debt Total | 142.122M | 188.867M | 130.965M | 115.143M | 45.212M |
| Other Stockholder Equity | 790.359M | 758.297M | 722.43M | 690.326M | 660.555M |
| Property Plant Equipment | - | 109.849M | 93.153M | 85.017M | 99.444M |
| Total Current Assets | 593.828M | 333.962M | 690.912M | 473.651M | 317.028M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | - | - | - | - | - |
| Net Receivables | 298.4M | 253.404M | 186.432M | 160.962M | 155.662M |
| Long Term Debt | - | - | - | - | - |
| Inventory | 0M | - | - | - | - |
| Accounts Payable | 31.869M | 33.069M | 25.678M | 26.552M | 22.404M |
| Accumulated Other Comprehensive Income | -10.072M | -12.392M | -4.846M | -0.131M | -2.741M |
| Non Currrent Assets Other | 24.97M | 21.129M | 17.422M | 8.794M | 9.477M |
| Non Current Assets Total | 1063M | 1018.533M | 969.023M | 917.026M | 826.043M |
| Capital Lease Obligations | 142.122M | 138.867M | 130.965M | 115.143M | 45.212M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -38.742M | -31.364M | -31.214M | -19.144M | -16.973M |
| Total Cashflows From Investing Activities | -38.742M | -31.364M | -31.214M | -19.144M | -16.973M |
| Total Cash From Financing Activities | -775.775M | -44.453M | -82.282M | -73.918M | -141.58M |
| Net Income | 245.368M | 181.848M | 145.384M | 100.443M | 73.185M |
| Change In Cash | -433.039M | 183.538M | 145.846M | 108.638M | -3.21M |
| Begin Period Cash Flow | 461.304M | 277.766M | 131.92M | 23.282M | 26.492M |
| End Period Cash Flow | 28.265M | 461.304M | 277.766M | 131.92M | 23.282M |
| Total Cash From Operating Activities | 388.05M | 263.327M | 258.676M | 201.867M | 156.584M |
| Depreciation | 22.341M | 21.119M | 19.528M | 23.189M | 38.801M |
| Other Cashflows From Investing Activities | -1.863M | -3.093M | 0.126M | -1.232M | -0.949M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | 24.982M | 5.53M | 21.256M | 27.788M |
| Sale Purchase Of Stock | -847.849M | -62.096M | -98.274M | 6.52M | 2.489M |
| Other Cashflows From Financing Activities | 346.274M | 17.643M | 15.992M | 6.52M | 0.608M |
| Capital Expenditures | 36.879M | 28.271M | 31.34M | 17.912M | 16.024M |
| Change In Working Capital | 106.055M | 66.707M | 66.257M | 35.588M | 39.601M |
| Other Non Cash Items | 15.888M | 16.296M | 13.196M | 11.856M | -5.444M |
| Free Cash Flow | 351.171M | 235.056M | 227.336M | 183.955M | 140.56M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | iShares Core S&P Mid-Cap ETF | 6 months ago | 830009 |
| 2. | Vanguard Total Stock Mkt Idx Inv | 6 months ago | 781572 |
| 3. | Vanguard Small Cap Index | 6 months ago | 633198 |
| 4. | Findlay Park American I USD Dist | 8 months ago | 462700 |
| 5. | Capital Group Fundamental Invtrs Comp | 9 months ago | 432367 |
| 6. | American Funds Fundamental Invs A | 6 months ago | 432367 |
| 7. | Vanguard Explorer Inv | 9 months ago | 421098 |
| 8. | Vanguard Institutional Extnd Mkt Idx Tr | 6 months ago | 386397 |
| 9. | Vanguard Small Cap Growth Index Inv | 6 months ago | 358581 |
| 10. | Invesco S&P MidCap Quality ETF | 6 months ago | 298753 |
| 11. | Wasatch Core Growth | 9 months ago | 234687 |
| 12. | FullerThaler Behavioral Sm-Cp Eq R6 | 9 months ago | 215268 |
| 13. | FullerThaler Behavioral Small-Cap Equity | 9 months ago | 215268 |
| 14. | SPDR® S&P MIDCAP 400 ETF Trust | 6 months ago | 212498 |
| 15. | UBS: US Equity Small Cap Growth | 1 year ago | 193521 |
| 16. | TD U.S. Capital Reinvestment I | 1 year ago | 178726 |
| 17. | TD Epoch Glb Qlty Capital Reinvestment | 9 months ago | 178389 |
| 18. | iShares Biotechnology ETF | 6 months ago | 165598 |
| 19. | ClearBridge Small Cap Growth A | 6 months ago | 161416 |
| 20. | ClearBridge Small Cap Growth | 6 months ago | 161416 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | BlackRock Inc | 9 months ago | 2686562 |
| 2. | Vanguard Group Inc | 9 months ago | 2545066 |
| 3. | Wasatch Advisors LP | 9 months ago | 908681 |
| 4. | State Street Corp | 9 months ago | 752957 |
| 5. | Geode Capital Management, LLC | 9 months ago | 628054 |
| 6. | Amvescap Plc. | 9 months ago | 565567 |
| 7. | Riverbridge Partners LLC | 9 months ago | 551644 |
| 8. | TD Asset Management Inc | 9 months ago | 503074 |
| 9. | Bessemer Group Inc | 9 months ago | 500769 |
| 10. | Renaissance Technologies Corp | 9 months ago | 492488 |
| 11. | Goldman Sachs Group Inc | 9 months ago | 486443 |
| 12. | Findlay Park Partners LLP | 9 months ago | 470900 |
| 13. | Capital World Investors | 9 months ago | 438365 |
| 14. | ClearBridge Advisors, LLC | 9 months ago | 417905 |
| 15. | TD Global Investment Solutions – TD Epoch | 9 months ago | 416219 |
| 16. | Wellington Management Company LLP | 9 months ago | 415255 |
| 17. | American Capital Management Inc | 9 months ago | 380646 |
| 18. | AQR Capital Management LLC | 9 months ago | 365750 |
| 19. | NORGES BANK | 1 year ago | 279585 |
| 20. | Dimensional Fund Advisors, Inc. | 9 months ago | 277355 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...